COVID-19 – External Monitoring Guidelines

Posted:

July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.

RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.

View Guidelines

‍

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021

Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.

View event

Making gains in drug development

September 2, 2021

Keith Berelowitz outlines the innovations in the design and delivery of clinical trials

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021

This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021

Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses.